Key Highlights

• 908 Devices reported Q2 2026 Revenue of $16.1 million, up 23 percent year-over-year, beating the $15.4 million estimate by 4.55 percent.

• Adjusted EBITDA loss improved 50 percent year-over-year to $1.9 million, with adjusted gross Margin rising to 57 percent from approximately 85 basis points a year ago.

• The company raised the low end of full-year 2026 revenue guidance to $68 to $70 million, representing 21 to 25 percent growth.

• The recently closed Neurolab Acquisition sold 35-plus subscription-based narcotics detection devices in approximately 60 days, with engagement from 30 agencies and hundreds of prospects.

Broad-Based Growth Across Core Product Lines Drives Beat

908 Devices Inc. (NASDAQ:MASS) reported second quarter revenue of $16.1 million, up 23 percent year-over-year, with U.S. state and local customers representing more than half of total revenues. 908 Devices designs, manufactures, and markets purpose-built handheld and portable mass spectrometry and Fourier transform infrared devices for vital health, safety, and defense applications, serving customers in law enforcement, public safety, defense, and biopharma sectors. Adjusted gross margin rose to 57 percent, up approximately 85 basis points year-over-year, while adjusted EBITDA loss improved 50 percent to $1.9 million from a larger loss in the prior-year period.

Management raised the low end of full-year 2026 revenue guidance to a range of $68 million to $70 million, representing 21 to 25 percent growth, with handheld product and service revenue now expected to grow 23 to 27 percent. OEM and funded Partnership revenue is expected to contribute approximately $3 million for the year, while the company's Avcd program with the Department of War remains excluded from core guidance, representing potential upside not currently reflected in the raised outlook.

Neurolab Acquisition Expands Reach Into AI-Powered Narcotics Detection

The company's acquisition of Neurolab, which closed in early May, is driving expansion into AI-powered subscription-based narcotics detection, with more than 35 devices sold in approximately 60 days following the close of the deal. Management said the Business has generated engagement with 30 agencies and hundreds of additional prospects, and the company is targeting a Recurring Revenue model for Neurolab of approximately 50 percent or higher, compared to the company-wide range of 30 to 31 percent recurring revenue historically.

Management said the acquisition strengthens the company's position in a growing market for portable narcotics detection technology used by law enforcement and public safety agencies, though the business remains in an early scaling phase and its longer-term contribution to overall company revenue and margin profile is still being established. The company said it expects continued contribution from Neurolab of approximately $1 million per quarter going forward.

Key Growth Drivers for the Second Half Include New Product Launches

Management cited several growth drivers for the second half of 2026, including the Viper FTIR device, which is targeting 100 to 150 units for the year, the Explorer gas and vapor detection platform, which has seen nearly 70 percent Placement growth over the trailing 12 months, and a new $6 million Protector order split between the third and fourth quarters. The company said its military CAD and Avcd program remains in flux, with the Department of War evaluating commercial off-the-shelf products, including 908's MX 908, against continuing custom development with Smiths Detection, and management expects more clarity once the Department's fiscal year 2027 begins on October 1.

Management characterized the potential Department of War opportunity as a greater than $10 million long-term prospect that remains excluded from current guidance given the uncertainty around program direction and timing, meaning any resolution favoring 908's commercial off-the-shelf approach could represent meaningful upside to current expectations, while an unfavorable outcome would not represent a downside to guidance already issued.

Conclusion

908 Devices delivered a quarter of broad-based growth across its core handheld product lines, supported by improving margins and a raised full-year revenue outlook, with the recently closed Neurolab acquisition adding a new subscription-based growth vector in narcotics detection. The company's decision to exclude both OEM funded partnership upside beyond current guidance and the Department of War's Avcd program from its outlook reflects a conservative approach to guidance that leaves room for potential positive catalysts later in the year. Continued scaling of Neurolab, the pace of Viper FTIR device placements, and eventual clarity on the Department of War's procurement direction are likely to be the key variables shaping results into 2027.